| Source | M.W. | 432.46 | CAS No. | 208255-80-5 | |
|---|---|---|---|---|---|
| Structural Info | C23H26F2N2O4 |
||||
| Formulation | Powder | ||||
| Reconstitution | Before reconstitution, we recommend a brief spin to drive down any material dislodged from the bottom of the tube. The compound is soluble in DMSO. | ||||
| Stability | The powder is stable for at least 2 year if stored at -20 °C. The dissolved compound is stable for at least 1 month at 4 °C, but should be stored in aliquots at -20 °C for longer term. Protect from light. | ||||
| Purity | Greater than 99% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request. | ||||
| Biological Activity | In a cell-based assay measuring the activation of the Notch pathway reporter gene, this compound gave IC50 of 500 nM. | ||||
| Country of Origin | USA | ||||
DAPT is a γ-secretase inhibitor that blocks Notch signaling. As an inhibitor of Notch, DAPT has been used to study autoimmune and lymphoproliferative diseases, such as ALPS and lupus erythematosus (SLE). As an inhibitor of γ-secretase with IC50 of 0.115 and 0.2 μM for total Aβ and Aβ42 levels, respectively, DAPT may be useful in the study of β-amyloid (Aβ) formation. It is shown to cause a reduction in Aβ40 and Aβ42 levels in human primary neuronal cultures and in brain extract, cerebrospinal fluid and plasma in vivo.